Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
75 studies found for:    cladribine
Show Display Options
Rank Status Study
1 Completed
Has Results
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
Condition: Multiple Sclerosis
Interventions: Drug: Cladribine;   Drug: Pantoprazole
2 Recruiting Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Condition: Multiple Sclerosis
Intervention: Drug: Cladribine
3 Recruiting Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Idarubicin;   Behavioral: Phone Calls
4 Recruiting Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Cladribine s.c. injection, HCL treatment
5 Recruiting Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
6 Recruiting Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Decitabine
7 Completed Cladribine in Patients With Mantle Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: cladribine
8 Recruiting 2CDA With Rituximab in Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
9 Unknown  Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
Condition: Leukemia, Myelocytic, Acute
Intervention: Drug: cladribine
10 Recruiting Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
11 Active, not recruiting Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis
Condition: Langerhans Cell Histiocytosis of Lung
Intervention: Drug: Cladribine
12 Active, not recruiting Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Conditions: Lymphoma;   Mantle Cell Lymphoma;   Indolent Lymphoma;   SLL
Interventions: Drug: rituximab;   Drug: bortezomib;   Drug: cladribine
13 Terminated R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukaemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Rituximab;   Drug: Cladribine
14 Completed Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
Condition: Hairy Cell Leukemia (HCL)
Intervention: Drug: 2CdA +/- Rituximab
15 Completed Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cladribine
16 Completed
Has Results
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Cladribine 5.25 mg/kg;   Drug: Cladribine 3.5 mg/kg;   Other: Placebo
17 Recruiting Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
18 Completed
Has Results
Oral Cladribine in Early Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: Cladribine;   Drug: Placebo;   Drug: Rebif® new formulation (RNF)
19 Recruiting Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Cladribine;   Procedure: Stem Cell Transplant;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cyclophosphamide
20 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Acute Biphenotypic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.